Abstract
Drs Newman and Maisels1 agree that the current management of hyperbilirubinemia in the term newborn is based on assumptions searching for scientific validation. As I was reading these letters I could not help but think about another "hot" topic occupying the "Letters to the Editor" section of Pediatrics—lead. As with lead-induced neurotoxicity, children practitioners cannot wait until there are data to fully guide decision making. In their article Newman and Maisels2 indicate some areas in the treatment of newborn hyperbilirubinemia in which there are wide disparities about the preferred management approach, and they identify those aspects of treatment that require a revised consensus statement to help guide therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
